Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/FC837726.svg?ark=w1%2F20260522%2FFC837726&value=id)](https://nobleid.org/work/w1/20260522/FC837726)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors